![uploads///Graph](https://media.marketrealist.com/brand-img/82a8oYvk8/640x335/uploads/2018/01/Graph-16-2-1.png 640w)
GSK Is Focused on Innovative Assets in Oncology Research Pipeline
In 2018, GlaxoSmithKline aims to initiate a pivotal phase 2 trial to evaluate GSK 916 as monotherapy Darzalex refractory population as the fourth line or the last line of multiple myeloma therapy.